Sexually transmitted disease detection kit Aptima®

HPVHPV 16molecular

The Aptima® HPV Assay and Aptima® HPV 16 18/45 Genotype Assay are molecular tests used in the detection of the human papillomavirus present in cervical samples. Powered by mRNA-based technology, they help detect both the presence and activity of high-risk HPV infections – offering equivalent sensitivity to DNA-based tests, with increased specificity.1-16 Increased Specificity Multiple studies have demonstrated that the Aptima HPV Assay provides equivalent sensitivity to DNA-based tests, with increased specificity.1-16 Fewer False Positives By targeting E6/E7 oncoproteins, the assays can identify the infections most likely to lead to disease — resulting in 24%-40% fewer false positives compared to DNA-based tests.17-19 Decade of Data The Aptima mRNA-based HPV assays showed extensive longitudinal safety data up to 10 years.11, 12, 20-22 Benefits of mRNA Testing mRNA based-technology helps to identify the infections most likely to lead to cervical cancer – supporting informed decision making and enabling laboratories and healthcare professionals to receive accurate and actionable results.17,18 A targeted and evidence-driven approach to molecular HPV testing. Targeted 16 18/45 genotyping, backed by data, identifies the infections associated with the highest risk of disease.17,18 Aptima HPV Assay Identifies active high-risk HPV Infections Test for all 14 high-risk genotypes with a single specimen. mRNA technology maximizes screening benefits while minimizing false positives for confidence in your results.1 Aptima HPV 16 18,45 Genotype Assay Box on white background Aptima HPV 16 18,45 Genotype Assay